Literature DB >> 3940225

CB 1954 revisited. II. Toxicity and antitumour activity.

P Workman, J E Morgan, K Talbot, K A Wright, J Donaldson, P R Twentyman.   

Abstract

We have assessed the antitumour activity of the nitrophenylaziridine CB 1954 in vitro and in vivo. For EMT6 mouse mammary tumour multicellular spheroids under hypoxic conditions in vitro, a 6-h exposure to 40 micrograms/ml reduced the surviving fraction to as low as 10(-3) and the growth delay was 5.4 days. Oxic cells were twofold less sensitive. Phenyl AIC protected oxic and hypoxic cells equally. Under oxic conditions minimal cell killing was seen with HT29 cells, either in multicellular spheroids or in monolayer; a 6-h exposure to 40 micrograms/ml gave a spheroid growth delay of 1.5-1.7 days. No growth delay was seen with single maximum tolerated doses of CB 1954 against HT29 grown as a xenograft in immunosuppressed mice. Only minimal growth delays of 1-2 days were seen with similar doses against the EMT6 tumour and the RIF-1 and KHT sarcomas in mice. Little activity was seen with maximum tolerated doses given once a day for 5 days against EMT6 and RIF-1. No chemosensitization was measurable with CCNU, cyclophosphamide or melphalan in the KHT tumour.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940225     DOI: 10.1007/bf00255279

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Medicinal nitro-compounds. Part II. Search for ortho-interactions in tumour-inhibitory 2,4-dinitrophenylaziridines.

Authors:  G A Butchart; M F Stevens; B C Gunn
Journal:  J Chem Soc Perkin 1       Date:  1975

2.  The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).

Authors:  M Jarman; D H Melzack; W C Ross
Journal:  Biochem Pharmacol       Date:  1976-11-15       Impact factor: 5.858

3.  Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. II.

Authors:  A H Khan; W C Ross
Journal:  Chem Biol Interact       Date:  1971-12       Impact factor: 5.192

4.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.

Authors:  P R Twentyman; R F Kallman; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

5.  Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).

Authors:  M J Tisdale; A D Habberfield
Journal:  Biochem Pharmacol       Date:  1980-10-15       Impact factor: 5.858

6.  In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.

Authors:  J M Yuhas; A E Tarleton; J G Harman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

7.  The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments.

Authors:  H M Warenius; L S Freedman; N M Bleehen
Journal:  Br J Cancer Suppl       Date:  1980-04

8.  Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide).

Authors:  I J Stratford; C Williamson; S Hoe; G E Adams
Journal:  Radiat Res       Date:  1981-12       Impact factor: 2.841

9.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

View more
  3 in total

1.  CB 1954 revisited. I. Disposition kinetics and metabolism.

Authors:  P Workman; R A White; K Talbot
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.